A method is for correcting a concentration of a bone turnover marker to obtain an adjusted value which gives an indication of an individual's bone health status or amount of changes occurred over time or by treatment while eliminating the influence of possible pre-analytical variability. The method includes: obtaining the concentration of the bone turnover marker of a sample; correcting the obtained concentration using a mathematical model which comprises at least three factors, different from the bone health status, such that for the adjusted value variabilities in the concentration of the bone turnover marker, that are caused by the at least three factors, are substantially filtered out by the mathematical model.

Provided herein is a method of treating bone resorption associated with osteoclastic activity in a subject in need thereof. The method includes reducing the level of FMS intracellular fragments (FICDs) in the subject.

Implant related risk of revision not caused by an infection or metal on metal reaction can be addressed by the methods provided herein, including diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.

The present invention discloses a novel therapeutic intervention for osteoporosis. The present invention discloses that Interleukin-3 (IL-3) can be utilized as a therapeutic intervention against osteoporosis and for regulating bone homeostasis. The present invention also provides a method for determining the pre-disposition of a subject for osteoporosis by measuring the RANKL/OPG level.

Implant related risk of revision not caused by an infection or metal on metal reaction can be addressed by the methods provided herein, including diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.

Methods for identifying subjects having bone loss by detecting bone microparticles in a sample of their bodily fluid are disclosed. Methods for monitoring bone loss and assessing efficacy of bone loss therapies by detecting bone microparticles in bodily fluid samples are also disclosed. Compounds for use as a negative control in the disclosed methods are provided as well as kits comprising such compounds.

The present invention relates to a biomarker for diagnosing rheumatoid arthritis, a biomarker for diagnosing osteoporosis as a complication of rheumatoid arthritis, a biomarker for predicting the severity and prognosis of rheumatoid arthritis, and a use thereof.

A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents that modulate Shn2 expression and/or activity, in addition to methods for modulating Shn2 and Shn3.

The disclosure discloses a biomarker in osteoporosis intervention therapy by bone peptide, the biomarker including a lipid and lipid-like molecule, an organic acid and its derivative, and/or a neurotransmitter, wherein the lipid and lipid-like molecule includes one or more of taurine, arachidonic acid, 1-palmitoyl-2-hydroxy-sn-glycerol-3-phosphoethanolamine, (4Z, 7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-docosahexaenoic acid, 1-stearoyl-2-hydroxy-sn-glycerol-3-phosphocholine, taurodeoxycholic acid, taurochenodeoxycholate or taurocholic acid. The disclosure discloses a screening method of a biomarker in the anti-osteoporosis activity of bone peptide. The disclosure discloses a use of the biomarker.